



Republic of the Philippines  
Department of Health  
**CENTRAL OFFICE BIDS AND AWARDS COMMITTEE**

**COBAC RESOLUTION NO. 2018-454**  
13 December 2018

**RECOMMENDING APPROVAL OF THE AWARD OF CONTRACT FOR THE PROCUREMENT OF  
PRAZIQUANTEL  
IB NO. 2018-093**

**WHEREAS**, Open Competitive Bidding for the Procurement of Praziquantel was conducted in accordance with Republic Act (RA) 9184 and its 2016 Implementing Rules and Regulations (IRR) through the General Appropriations Act of 2018 with a Total Approved Budget for the Contract of *Eighty Four Million Two Hundred Eighty Thousand Philippine Pesos (PhP84,280,000.00)*;

Item No.	Description	Qty.	Unit	Total ABC (PhP)
1	Praziquantel	12,040,000	Tablet or caplet	84,280,000.00

**WHEREAS**, Purchase Request (PR) was received from Disease Prevention Control Bureau (DPCB) -- Infectious Diseases for Elimination Division (IDED);

**WHEREAS**, on 20 February 2018, a Pre-procurement Conference was conducted at 10:00 AM at the COBAC Conference Room, DOH to determine the readiness of the procurement at hand;

**WHEREAS**, on 26 February 2018, the Invitation to Bid (IB) was posted in the PhilGEPS website and other conspicuous places within the premises of the DOH. The advertisement of IB in a newspaper of general nationwide circulation provided in Section 21.2.1 (c) shall not be required for contracts to be bid with an ABC of Ten Million Pesos (P10,000,000.00) and below for the procurement of goods;

**WHEREAS**, the Technical Working Group (TWG) was created through the issuance of Department Personnel Order (DPO) COBAC No. 2018-118 dated 05 March 2018;

**WHEREAS**, a Bid Bulletin No. 1, dated 05 March 2018, was issued to announce the new schedule of the Pre-bidding Conference;

**WHEREAS**, on 07 March 2018, a Pre-bidding Conference was conducted as re-scheduled at 9:00 AM at the COBAC Conference Room, DOH, with four (4) prospective bidders participating namely:

- 1) Zuellig Pharma Corp. (ZPC);
- 2) Phil Pharmawealth Inc. (PPI);
- 3) RBC-MDC Corp. (RCB-MDC); and
- 4) AM-Europharma Corp. (AMEC).

**WHEREAS**, during the said Pre-bidding Conference, clarifications on the eligibility requirements and technical specifications were discussed;

**WHEREAS**, on the same date, the COBAC-A issued a memorandum to DPCB-IDEED on the issues and questions raised during the Pre-bidding Conference;

**WHEREAS**, on 09 March 2018, a letter from PPI was received requesting for clarification on the schedule of requirement of the said procurement project and was acknowledged through electronic mail (e-mail) on 19 March 2018;

**WHEREAS**, a Bid Bulletin No. 2, dated 15 March 2018, was issued to announce the postponement until further notice of the Submission and Opening of Bids previously set on 20 March 2018;

**WHEREAS**, on the same date, DPCB submitted its response on the issue and concern raised during the Pre-bidding Conference;

CERTIFIED TRUE COPY

THEA ORTIZ

**WHEREAS**, on the same date, a letter from PPI was received regarding its Manifestation on Various DOH Procurement Activities which was acknowledged through email on 19 March 2018;

**WHEREAS**, on 19 March 2018, the Committee forwarded PPI's manifestation to the End-user, DPCB;

**WHEREAS**, a Bid Bulletin No. 3, dated 19 March 2018, was issued to clarify the issues and questions raised during the Pre-bidding Conference and to announce the new schedule of the Submission and Opening of Bids;

**WHEREAS**, a Bid Bulletin No. 4, dated 22 March 2018, was issued to announce the new schedule of the Submission and Opening of Bids and the changes in the Bidding documents;

**WHEREAS**, a Bid Bulletin No. 5, dated 27 March 2018, was issued to respond on the clarification of PPI relative to the requirement of commercial availability in the Philippine Market for the past two (2) years;

**WHEREAS**, the Submission of Bids took place as re-scheduled on 03 April 2018 at 9:00 A.M. at the COBAC Conference Room, Ground Floor, Bldg. 6, DOH;

**WHEREAS**, three (3) prospective bidders submitted their respective proposals, namely:

- 1) PPI;
- 2) AMEC; and,
- 3) MedEthix Inc. (MEI).

**WHEREAS**, on the same date, Notice of Change of Schedule was issued to announce the new schedule of the Opening of Bids since the Committee were not available during the said activity;

**WHEREAS**, on the same date, PPI filed its Motion for Reconsideration (MR) on Bid Bulletin No. 5;

**WHEREAS**, on 06 April 2018, DPO No. 2018-1282 "Reconstitution of the Central Office Bids and Awards Committee to Process 2018 Procurement and Definition of Functions and Responsibilities" was posted;

**WHEREAS**, the Opening of Bids took place as re-scheduled on 06 April 2018 at 9:00 A.M. at the COBAC Conference Room, Ground Floor, Bldg. 6, DOH, with three (3) prospective bidders, participating, namely:

- 1) PPI;
- 2) AMEC; and,
- 3) MEI.

**WHEREAS**, the first envelopes, containing the Eligibility and Technical Document were individually opened and the presence, completeness and correctness of all the documents were verified by the COBAC-A in the presence of the prospective bidders' representative. Upon examination, all three (3) bidders were declared "ELIGIBLE;"

**WHEREAS**, the second envelopes, containing the Financial Proposal were individually opened and the presence, completeness and correctness of the Financial Documents were verified by the COBAC-A in the presence of the bidders' representative. Upon examination, all three (3) "ELIGIBLE" bidders were rated "PASSED" and subsequently its bids were read out publicly and posted in the Abstract of Bid, to wit:

Name of Company					PPI	AMEC	MEI
Bid Security					BID SECURING DECLARATION		
Amount					N/A		
Validity					N/A		
REMARKS					ELIGIBLE / PASSED		
Item No.	Item Description	Qty.	Unit	TOTAL ABC (PhP)	BID PRICE AS READ (PhP)		
1	Praziquantel	12,040,000	tablet	84,280,000.00	59,477,600.00	61,993,960.00	63,571,200.00

**WHEREAS**, PPI was declared as the Lowest Bidder (LB) subject to further arithmetical review and corrections of the financial bid to determine the bona fide Lowest Calculated Bid (LCB);

**WHEREAS**, the bids for the item listed below were found to be substantially complying:

12,040,000 tablets of Praziquantel

Bidder No.	Name of Company	ABC (PhP)	Bid as Calculated Amount (PhP)	% Variance from ABC
1	PPI	84,280,000.00	59,477,600.00	29.42%
2	AMEC		61,993,960.00	26.44%
3	MEI		63,571,200.00	24.57%

**WHEREAS**, on 06 April 2018, the MR filed by PPI was presented to COBAC-A during its 14<sup>th</sup> Regular Meeting. Upon deliberation, the Committee retained the requirement of commercial availability in the Philippine market for the past two (2) years in the Bidding documents and resolved to deny PPI's MR;

**WHEREAS**, on 10 April 2018, the Committee issued a notification through email to PPI informing the denial of its MR on Bid Bulletin No.5;

**WHEREAS**, on the same date, the Bid Evaluation of the submitted proposal of PPI on the legal, technical and financial aspects was undertaken by the designated TWG;

**WHEREAS**, on 17 April 2018, PPI filed its verified Position paper to the HoPE with appropriate protest fee on the denial of its MR on Bid Bulletin No.5;

**WHEREAS**, on 18 April 2018, a letter from PPI was received requesting for a copy of Minutes of the Pre-bidding documents;

**WHEREAS**, on the same date, the Position paper and its request for a copy of minutes of Pre-bidding Conference was presented to COBAC-A. Upon deliberation, the Committee granted its request for a copy of the said minutes; further, instructed to endorse the Position paper to Legal Service (LS), for appropriate action;

**WHEREAS**, on the same date, the Position paper was endorsed to LS;

**WHEREAS**, on 19 April 2018, through a letter sent through email, PPI was informed that its request for a copy of minutes was granted by the Committee;

**WHEREAS**, on 19, 24,30 April 2018, various letters informing that the Position paper is still on review was issued to PPI;

**WHEREAS**, on 25 April 2018, the TWG found the LCB, PPI compliant with the Legal and Financial requirements, however, one of the technical evaluator found the bidder non-compliant with the requirement as to *proof of commercial availability in the Philippine market for the past two (2) years*;

**WHEREAS**, on 08 and 17 of May 2018, letters informing that the Position paper is still on review was issued through facsimile to PPI;

**WHEREAS**, on 09 May 2018, the TWG evaluation report was presented to COBAC-A. Upon deliberation, the Committee instructed to endorse the report to the end-user;

**WHEREAS**, however, given that there is a pending protest on Bid Bulletin No.5 and also one of the technical evaluator was from the End-user, the said report was no longer endorsed, but was presented again to COBAC-A and decided to wait for the resolution of PPI's protest;

**WHEREAS**, on 21 May 2018, a copy of the decision to deny the protest on Bid Bulletin No.5 to PPI on 18 May 2018 was received from LS;

**WHEREAS**, on 22 May 2018, the decision on PPI's protest on Bid Bulletin No.5 and the TWG evaluation report of PPI as the LCB was presented to COBAC-A during its 20<sup>th</sup> Regular Meeting. Upon deliberation, the Committee, noted the decision and decided to clarify the technical findings on the proof of commercial availability to PPI;

**WHEREAS**, on 29 May 2018, a clarification letter on the technical findings was issued through email to PPI;

**WHEREAS**, on 31 May 2018, PPI filed its MR on the denial of its Protest on Bid Bulletin No.5 which was acknowledged through email on 08 June 2018;

**WHEREAS**, on 01 June 2018, PPI submitted its response on the COBAC-A's clarification on the technical findings regarding the proof of commercial availability in the Philippine market for the past two (2) years for Praziquantel;

**WHEREAS**, on 05 June 2018, the said MR on the denial of PPI's protest was presented to COBAC-A during its 22<sup>nd</sup> Regular Meeting. Upon deliberation, the Committee instructed to forward the said MR to LS, for action;

**WHEREAS**, on the same date, PPI's response clarifying the technical finding was also presented to COBAC-A during the said meeting. Upon deliberation, the Committee declared PPI "non-compliant" on the commercial availability requirement given since the pro-forma invoice submitted was for 2017 only and the Certificate of Product Registration (CPR) cannot suffice the requirement that the product is available in the market for the past two (2) years, and to proceed with the evaluation of the second (2<sup>nd</sup>) LCB, AMEC;

**WHEREAS**, on the same date, a notice of non-compliance was issued through email to PPI;

**WHEREAS**, on 08 June 2018, PPI filed its Request for Reconsideration (RFR) on its non-compliance to 2 years commercial availability requirement which was acknowledged through email and facsimile on 18 June 2018;

**WHEREAS**, on 11 June 2018, the Committee, through a memorandum endorsed PPI's RFR on the denial of its protest on Bid Bulletin No.5 to LS;

**WHEREAS**, on 13 June 2018, PPI's RFR on the notice of non-compliance was presented to COBAC-A during its 23<sup>rd</sup> Regular Meeting. Upon deliberation, the Committee instructed to endorse the RFR to LS;

**WHEREAS**, on 18 June 2018, through a memorandum, the Committee endorsed the RFR on the notice of non-compliance to LS;

**WHEREAS**, on 20 and 21 June 2018, a letter from PPI was received requesting certified true copies of various documents in connection with the Procurement of Praziquantel which was acknowledged on 29 June 2018;

**WHEREAS**, on 21 June 2018, a memorandum from LS was received in response to the RFR filed by PPI on its non-compliance requesting the COBAC to resolve the matter based on RA 9184;

**WHEREAS**, on 29 June 2018, various letters was issued through email to PPI on the status of the following RFRs:

- a) RFR on the denial of Protest to Bid Bulletin No.5; and,
- b) RFR on declaration of non-compliance to the 2 years commercial availability.

**WHEREAS**, on 03 July 2018, PPI's request for certified copy of documents was presented to COBAC-A during its 25<sup>th</sup> Regular Meeting. Upon deliberation, the COBAC-A granted its request. Further, the memorandum from LS was also presented, upon deliberation, the Committee decided to wait for the resolution of PPI's MR on the denial of its protest to Bid Bulletin No. 5;

**WHEREAS**, several follow-ups were made by the Secretariat to LS on the status of the resolution of the MR filed by PPI relative to the denial of protest on Bid Bulletin No. 5;

**WHEREAS**, on 20 July 2018, letters were issued to PPI, AMEC, and MEI through e-mail and facsimile requesting for extension of their bid validity and bid security for another sixty (60) calendar days pursuant to Section 28.2 of the 2016 IRR of RA 9184:

**WHEREAS**, on 23 July 2018, PPI submitted its extension of Bid validity and Bid security;

**WHEREAS**, on 24 July 2018, AMEC submitted its extension of Bid validity and Bid security;

**WHEREAS**, on 25 July 2018, MEI submitted its extension of Bid validity and Bid security;

**WHEREAS**, on 28 July 2018, PPI's bid validity and security extension was presented to the COBAC-A during its 28<sup>th</sup> Regular Meeting. Upon deliberation, the Committee noted the information;

**WHEREAS**, on 30 July 2018, a memorandum from LS was received relative to the status of the draft resolution on the MR on the protest to Bid Bulletin No. 5 filed by PPI;

**WHEREAS**, on the same date, the TWG found the 2<sup>nd</sup> LCB, AMEC, compliant as to Legal, Financial, and Technical requirements and submitted its evaluation report;

**WHEREAS**, on 02 August 2018, a copy of resolution to the MR on the denial of protest to Bid Bulletin No. 5 filed by PPI was received;

**WHEREAS**, on the same date, AMEC's and MEI's bid validity and bid security extension was presented to COBAC-A during its 29<sup>th</sup> Regular Meeting, wherein the latter noted the information. Further, the memorandum from LS was also presented, in which the Committee also noted;

**WHEREAS**, on 08 August 2018, the resolution to PPI's RFR on the denial of its protest to Bid Bulletin No. 5 was presented to COBAC-A. Upon deliberation, the Committee noted the resolution and decided to deny its RFR on its non-compliance to 2 year commercial availability requirement. Further, the Committee also confirmed the documents to be issued to PPI;

**WHEREAS**, on the same date, a letter was issued to PPI informing the denial of its RFR relative to the commercial availability requirement;

**WHEREAS**, on 09 August 2018, the certified copy of documents as requested was issued to PPI;

**WHEREAS**, on the same date, another letter from PPI was received requesting for a copy of minutes of Opening of Bids;

**WHEREAS**, on 10 August 2018, a letter from PPI was received re: "Manifestation on the denial of Request for Reconsideration (RFR) on the Post-disqualification for the procurement of Praziquantel" which was acknowledged on 14 August 2018;

**WHEREAS**, on 14 August 2018, given that MR and RFR filed by PPI was already resolved, the TWG evaluation report on the bid of AMEC was presented to COBAC-A and decided to proceed with the evaluation of post-qualification documents upon receipt of thereof;

**WHEREAS**, on the same date, a letter was issued to PPI informing that a copy of minutes of meeting of Opening of Bids was already included in the documents issued last 09 August 2018;

**WHEREAS**, on the same date, a notification was issued to AMEC through e-mail, requesting for the submission of post-qualification requirements;

**WHEREAS**, on 15 and 21 August 2018, another letter requesting certified true copies of various documents relative to the procurement of Praziquantel was received from PPI;

**WHEREAS**, on 15 August 2018, PPI filed its protest on the denial of its RFR to its non-compliance of the 2-year commercial availability requirement which was acknowledged on 20 August 2018;

**WHEREAS**, on 20 August 2018, AMEC submitted its post-qualification documents which were considered within the prescribed timelines taking into consideration that the last day in the period of prescription falls on a Sunday which is a non-working day. Further, the said documents were subsequently forwarded to the designated TWG, for evaluation;

**WHEREAS**, on 22 August 2018, through a memorandum, the latest protest of PPI was forwarded to LS, for appropriate action;

**WHEREAS**, on 28 August 2018, a letter was issued to PPI informing that the protest dated 15 August 2018 is still for Legal review;

**WHEREAS**, on 30 August 2018, the COBAC-A requested the Head of the Procuring Entity (HoPE) through its Assistant Secretary of Health of Technical Service Cluster (TSC) for the extension of the post-qualification evaluation in accordance with Section 34.8 of the RA 9184 and its 2016 IRR, states that the post-qualification process shall be completed in not more than twelve (12) calendar days from the determination of the Lowest Calculated Bid/Highest Rated Bid. In exceptional cases, the post-qualification period may be extended by the HoPE, but in no case shall the aggregate period exceed forty-five (45) calendar days for Goods and Infrastructure Projects, or thirty (30) calendar days in Consulting Services;

**WHEREAS**, on the same date, the TWG found AMEC "responsive" with the technical post-qualification requirement and requesting clarification on the financial requirement as to EFPS payment details and legal requirement as to 3<sup>rd</sup> quarter payment of Mayor's/Business Permit;

**WHEREAS**, on 31 August 2018, two (2) certified true copies of documents was issued to PPI;

**WHEREAS**, on 11 September 2018, a letter was issued to PPI informing that the protest filed last 15 August 2018 is still on review;

**WHEREAS**, on the same date, the TWG post-qualification report was presented to COBAC-A during its 35<sup>th</sup> Regular Meeting. Upon deliberation, the Committee decided to clarify the findings on AMEC's bid pending the resolution to the protest filed by PPI;

**WHEREAS**, on 13 September 2018, a letter was issued to AMEC requesting to clarify the financial and legal TWG findings;

**WHEREAS**, on the same date, AMEC submitted the requested documents for verification through e-mail, which was subsequently forwarded to the TWG for further evaluation;

**WHEREAS**, on 21 September 2018, another letter from PPI was received requesting certified true copies of documents in connection with the procurement of Praziquantel;

**WHEREAS**, on 02 October 2018, the above cited letter was presented to COBAC-A during its 37<sup>th</sup> Regular Meeting. Upon deliberation, the Committee granted PPI's request for copies of documents;

**WHEREAS**, on 03 October 2018, the TWG found AMEC "responsive" with the financial and legal post-qualification requirements based on the submitted documents and submitted its final TWG post-qualification report;

**WHEREAS**, on the same date, a copy of the Petition for Certiorari filed by PPI even when the protest was not officially acted upon was received, which was forwarded to LS through a memorandum on 04 October 2018;

**WHEREAS**, on 04 October 2018, a memorandum from LS was received re: Draft Decision on the Protest filed by Phil Pharmawealth Inc. for the Procurement of Praziquantel. Further, two (2) copies of certified documents were provided to PPI;

**WHEREAS**, on 05 October 2018, a hearing on the TRO filed by PPI was held at Branch 12 RTC Manila;

**WHEREAS**, on the same date, a notice was received from PPI informing that the bidder filed with the Regional Trial Court (RTC) of Manila on 01 October 2018 an original action for Certiorari against the DOH;

**WHEREAS**, on 08 October 2018, a copy of the decision to deny the latest Protest filed by PPI dated 15 August 2018 was received by the Secretariat;

**WHEREAS**, on 09 October 2018, during the COBAC-A's 38<sup>th</sup> Regular Meeting, the Decision on the latest Protest filed by PPI as well as the final TWG post-qualification report for the 2<sup>nd</sup> LCB, AMEC were presented. Upon deliberation, the Committee noted the decision on the protest. Further, the Committee instructed to clarify with the LS if the COBAC-A is allowed to recommend the award of contract to the 2<sup>nd</sup> LCB. Also, during the said meeting, the copy of the Petition to Certiorari as well as the Application for Temporary Restraining Order (TRO) filed by PPI were also presented which the Committee noted since the documents were already forwarded to LS.

**WHEREAS**, on the same date, an Order from RTC Manila was received on PPI's application for TRO including the decision of RTC informing the denial of PPI's application;

**WHEREAS**, on 11 October 2018, a copy of the Decision on the latest Protest filed by PPI dated 15 August 2018 was received;

**WHEREAS**, on 16 October 2018, the aforementioned Order from RTC and its decision was presented to COBAC-A during its 39<sup>th</sup> Regular Meeting. Upon deliberation, the Committee noted the said decision;

**WHEREAS**, on 17 October 2018, a copy of the Petition for Certiorari filed by PPI was forwarded to Government Procurement Policy Board Technical Support Office (GPPB-TSO);

**WHEREAS**, on 18 October 2018, a meeting was held with the Office of the Solicitor General (OSG) relative to the hearing for preliminary injunction. Further, on the same meeting, the OSG representative advised that the award of contract be put on hold considering the proceedings of the case filed for Praziquantel;

**WHEREAS**, on 19 October 2018, a memorandum was issued to DPCB forwarding the queries of OSG relative the technical requirement as to "*Must be commercially available in the Philippine market for the past two (2) years*,"

**WHEREAS**, on the same date, acknowledgement from GPPB-TSO was received;

**WHEREAS**, on 22 October 2018, DPCB submitted its response on the queries of OSG;

**WHEREAS**, on 24 October 2018, hearing for the Preliminary Injunction was held at Branch 12 RTC Manila;

**WHEREAS**, on 29 October 2018, Order from RTC was received on the hearing held last 24 October 2018;

**WHEREAS**, on 30 October 2018, a meeting with OSG representative, with the End-user, DPCB, and Legal representative was held regarding the initial presentation of respondents' evidence scheduled on 07 November 2018;

**WHEREAS**, on 05 November 2018, a copy of Judicial Affidavit (JA) was submitted;

**WHEREAS**, on 07 November 2018, hearing for Preliminary Injunction was held at Branch 12 RTC Manila wherein the respondent presented its witness;

**WHEREAS**, on 08 November 2018, letters were issued to PPI, AMEC, and MEI through e-mail and facsimile requesting for extension of their bid validity and bid security until 31 December 2018 pursuant to Section 28.2 of the 2016 IRR of RA 9184;

**WHEREAS**, on 12 November 2018, AMEC submitted its extension of Bid validity and security;

**WHEREAS**, on 13 November 2018, a letter from PPI was received informing that they can no longer issue an extension of their BSD and bid proposal;

**WHEREAS**, on 15 November 2018, the aforementioned bid validity and security extension of AMEC and the letter of PPI was presented to COBAC-A during its 42<sup>nd</sup> Regular Meeting. Upon deliberation, the Committee noted the information. However, on the letter of PPI, the COBAC instructed the Secretariat to seek clarification on the letter of PPI with LS;

**WHEREAS**, on the same date, upon consultation with GPPB-TSO, pursuant to Section 28.1 of RA 9184 *Bids and bid securities shall be valid for a reasonable period as determined by the HoPE concerned, which shall be indicated in the Bidding Documents, but in no case shall the period exceed one hundred twenty (120) calendar days from the date of the opening of bids. Further pursuant to Section 28.2 Bidders, however, shall have the right to refuse to grant such extension without forfeiting their bid security;*

**WHEREAS**, on the same date, Order from Branch 12 RTC Manila was received relative to the hearing held last 07 November 2018;

**WHEREAS**, on 21 November 2018, the hearing for preliminary injunction was held wherein the counsel of PPI continued its cross examination with the respondent's witness;

**WHEREAS**, on the same date, through a letter, the Procurement Service (PS) seeks GPPB's interpretation on the propriety on the award of contract despite pending case for Injunction for the said project;

**WHEREAS**, on 22 November 2018, a letter was issued to PPI in response to its clarification on the extension of bid validity and security;

**WHEREAS**, on 29 November 2018, Order from Branch 12 RTC Manila was received relative to the hearing held last 21 November 2018;

**WHEREAS**, on 10 December 2018, a copy of the Order from Branch 12 RTC Manila was received through email informing that PPI's application for a Writ of Preliminary Injunction is denied;

**WHEREAS**, on 11 December 2018, the TWG report on the Post-qualification documents of AMEC was again presented to COBAC-A together with the Order/Decision of RTC to COBAC –A during its 44<sup>th</sup> Regular Meeting. Upon review and deliberation, the Committee concurred with the TWG report and declared AMEC “post-qualified” for the said item and noted the decision of RTC;

**WHEREAS**, on 12 December 2018, the TWG submitted the Bid Evaluation and Post Qualification Evaluation Reports citing AMEC “responsive” on the submitted documents and response;

**WHEREAS**, on the same date, the COBAC-A reviewed and deliberated the TWG reports, as well as the documents and response submitted by AMEC. The following are the salient points of discussion:

Item No.	Description	Name of Bidder	Bidder's Rank	ABC (Php)	Bid Price (Php)	TWG		COBAC	
						Finding	Recommendation	Finding	Recommendation
1	12,040,000 tablets of Praziquantel	AMEC	2 <sup>nd</sup> LCB	84,280,000.00	61,993,960.00	The 2 <sup>nd</sup> LCB passed the post qualification and found to have complied with the legal, technical and financial requirements and submitted response	Responsive	COBAC conforms with the recommendation of the TWG. • AMEC is determined to be responsive and post-qualified and recommended for the award of contract	Lowest Calculated and Responsive Bid (LCRB)

WHEREAS, at the time of the signing of this resolution, there is no pending incident, no pending Motion for Reconsideration, no pending Protest and the COBAC-A followed the requirements set forth in R.A. 9184;

NOW THEREFORE, on the basis of the above, the herein members of the COBAC-A HEREBY RESOLVE to recommend the award of contract to **AM-Europharma Corp.** determined as the LCRB with a Total Contract Price of **Sixty One Million Nine Hundred Ninety Three Thousand Nine Hundred Sixty Philippine Pesos (PhP61,993,960.00)** inclusive of other taxes for the item listed below:

Item/No.	Particular	Qty.	Unit	Total Amount (PhP)
1	Praziquantel	12,040,000	Tablet	61,993,960.00

Signed this 05<sup>th</sup> of July 2018 at the Department of Health, San Lazaro Compound, Sta. Cruz, Manila.

**CENTRAL OFFICE BIDS AND AWARDS COMMITTEE (COBAC) – A**

**LEONITA P. GORGOLON, MHA, MCHM, CEO VI**  
Regular Member

**KENNETH G. RONQUILLO, MD, MPH, CESO III**  
Vice-Chairperson

**FERCHITO L. AVELINO, MD, PHSAE**  
Regular Member

**MAR WYNNE C. BELLO, MD, MPA**  
Regular Member

**NESTOR F. SANTIAGO, JR., MD, MPH, C, MHSA, CESO III**  
Assistant Secretary of Health  
Chairperson

By Authority of the Secretary of Health:

**MARIA ROSARIO S. VERGEIRE, MD, MPH, CESO IV**  
Assistant Secretary of Health  
Public Health Service Team

DEC 28 2018

CERTIFIED TRUE COPY  
**THEA ORTIZ**